Pharmaceutical Executive-12-01-2004
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
2
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
3
The Next Chapter in Metabolic Drug Development
4
How a Shift Towards Oral Medications Impacts GLP-1s
5